0.075% capsaicin lotion for the treatment of peripheral neuropathy in ESRD patient: A randomized double-blind placebo-controlled, cross over trial

Phase 3

Recruiting

• Conditions: End stage kidney diseaseNeuropathic painDefined as neuropathic pain diagnostic questionnaire (Thai DN4); End stage renal disease; Chronic kidney disease; Neuropathic pain; Capsicin; Quality of life

• Registration Number: TCTR20200820005
• Lead Sponsor: Department of Medicine, Phramongkutklao Hospital

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Start: 2020-08-20
• Study Completion: 2021-05-31
• Last Update Posted: 19 August 2024

Recruitment & Eligibility

• Status: Recruiting
• Sex: All
• Target Recruitment: 60

Inclusion Criteria

1. Age ≥ 20 years old
2. End stage renal disease patient
3. The scores of neuropathic pain diagnostic questionnaire (Thai DN4) are 4-8
4. Participants have moderate neuropathic pain more than 1 month
5. Participants who have been using other standard pain control pills, should take the same dose for more than 4 weeks.

Exclusion Criteria

1. Participants who have severe side effect of 0.075% capsicin gel.

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Reduction of neuropathic pain in ESRD patient Every 2 weeks for 18weeks Visual analog score

Secondary Outcome Measures

Name	Time	Method
Quality of life Every 2 weeks for 18weeks KDQOL-SF,Characteristic of neuropathic pain Every 2 weeks for 18weeks Short-form McGill pain questionnaire